These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28550040)

  • 1. KRAS
    Kamata T; Giblett S; Pritchard C
    Blood; 2017 Jul; 130(4):514-526. PubMed ID: 28550040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
    Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
    Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis.
    Murakami I; Matsushita M; Iwasaki T; Kuwamoto S; Kato M; Nagata K; Horie Y; Hayashi K; Imamura T; Morimoto A; Imashuku S; Gogusev J; Jaubert F; Takata K; Oka T; Yoshino T
    Cell Commun Signal; 2015 Feb; 13():13. PubMed ID: 25889448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
    Tran G; Huynh TN; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
    Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
    Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.
    Mourah S; How-Kit A; Meignin V; Gossot D; Lorillon G; Bugnet E; Mauger F; Lebbe C; Chevret S; Tost J; Tazi A
    Eur Respir J; 2016 Jun; 47(6):1785-96. PubMed ID: 27076591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
    Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
    Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique dependence on Sos1 in
    You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
    Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?
    Berres ML; Merad M; Allen CE
    Br J Haematol; 2015 Apr; 169(1):3-13. PubMed ID: 25430560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.
    Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO
    Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
    Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE
    J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis.
    Chilosi M; Facchetti F; Caliò A; Zamò A; Brunelli M; Martignoni G; Rossi A; Montagna L; Piccoli P; Dubini A; Tironi A; Tomassetti S; Poletti V; Doglioni C
    Leuk Lymphoma; 2014 Nov; 55(11):2620-6. PubMed ID: 24471909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between clinicopathologic characteristics and BRAF
    Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
    Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis.
    Xiao Y; van Halteren AGS; Lei X; Borst J; Steenwijk E; de Wit T; Grabowska J; Voogd R; Kemps P; Picarsic J; van den Bos C; Borst J
    Blood; 2020 Nov; 136(19):2188-2199. PubMed ID: 32750121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.
    Satoh T; Smith A; Sarde A; Lu HC; Mian S; Trouillet C; Mufti G; Emile JF; Fraternali F; Donadieu J; Geissmann F
    PLoS One; 2012; 7(4):e33891. PubMed ID: 22506009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.
    Okayama H; Saito M; Oue N; Weiss JM; Stauffer J; Takenoshita S; Wiltrout RH; Hussain SP; Harris CC
    Int J Cancer; 2013 Jan; 132(1):9-18. PubMed ID: 22618808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of SIRPα as a potential therapy for Langerhans cell histiocytosis.
    Okamoto T; Murata Y; Hasegawa D; Yoshida M; Tanaka D; Ueda T; Hazama D; Oduori OS; Komori S; Takai T; Saito Y; Kotani T; Kosaka Y; Maniwa Y; Matozaki T
    Cancer Sci; 2023 May; 114(5):1871-1881. PubMed ID: 36788737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci.
    Egeler RM; Katewa S; Leenen PJ; Beverley P; Collin M; Ginhoux F; Arceci RJ; Rollins BJ;
    Pediatr Blood Cancer; 2016 Oct; 63(10):1704-12. PubMed ID: 27314817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.